Abstracts tagged "morbidity and mortality and vasculitis"

Abstract Number: 1771 • 2017 ACR/ARHP Annual Meeting
Prevalence and Prognostic Relevance of Cardiovascular Involvement in ANCA-Associated Vasculitis: A Retrospective Cohort Study
Qin Huang¹, Hao Ren¹, Yaping Zhan², Shenyi Yu² and Min Yang¹, ¹Department of Rheumatology, Nanfang Hospital，Southern Medical University, Guangzhou, China, ²Department of rheumatology, Nanfang Hospital，Southern Medical University, Guangzhou, China
Background/Purpose: Cardiovascular involvement in ANCA-associated vasculitis (AAV) including microscopic polyangiitis (MPA), eosinophilic granulomatosis with polyangiitis (EGPA) and granulomatosis with polyangiitis (GPA), has long been regarded…
Abstract Number: 2736 • 2017 ACR/ARHP Annual Meeting
Long-Term Survival in Systemic Necrotizing Vasculitides
Sabine Jardel¹, Xavier Puéchal², Alain Le Quellec³, Matthieu Groh², Mohamed Hamidou⁴, Francois Maurier⁵, Olivier Aumaître⁶, Achille Aouba⁷, Thomas Quémeneur⁸, Jean-François Subra⁹, Vincent Cottin¹⁰, Pascal Godmer¹¹, Patrice Cacoub¹², Philippe Delaval¹³, Anne-Laure Fauchais¹⁴, Eric Hachulla¹⁵, Delphine Maucort-Boulch¹⁶, Loïc Guillevin² and Jean-Christophe Lega¹⁷, ¹Lyon 1 University, Lyon, France, ²National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ³Montpellier, Montpellier, France, ⁴Internal Medicine Department, Internal Medicine Department, Nantes University Hospital, Nantes, France, ⁵Internal Medicine, Sainte-Blandine de Metz Hospital, Metz, France, ⁶CHU Pitié-Salpêtrière - Department of Internal Medicine 2. Referal center for SLE/APS, Paris, France, ⁷Department of Internal Medicine, Caen University Hospital, Caen, France, ⁸Service de néphrologie, médecine interne et vasculaire, Hôpital de Valenciennes, Valenciennes, France, ⁹Angers, Angers, France, ¹⁰Louis Pradel Hospital, Claude Bernard University Lyon 1, Lyon, France, ¹¹Medecine Interne, CH Vannes, Vannes, France, ¹²Department of Internal Medicine and Clinical Immunology, Groupe Hospitalier Pitié-Salpêtrière, Paris, France, ¹³Rennes, Rennes, France, ¹⁴Internal Medicine, Internal Medicine, Limoges, France, ¹⁵CHU Lille, Département de Médecine Interne et Immunologie Clinique, F-59000 Lille, France, Lille, France, ¹⁶Biostatistics and bioinformatics, Centre Hospitalier Lyon Sud - Claude Bernard University Lyon 1, Lyon, France, ¹⁷Department of Internal and Vascular Medicine, Lyon Sud Hospital, Hospices Civils de Lyon, Lyon, France
Background/Purpose: The aim of the study was to describe the evolution of mortality over recent decades in systemic necrotizing vasculitides, including polyarteritis nodosa (PAN), granulomatosis…
Abstract Number: 1002 • 2017 ACR/ARHP Annual Meeting
Survival and Years of Potential Life Lost in Connective Tissue Disease and Vasculitis; Data from the Norwegian Connective Tissue Diseases and Vasculitis Registry (NOSVAR)
Torhild Garen¹, Karoline Lerang¹, Anna Maria Hoffmann-Vold², Helena Andersson¹, Øyvind Midtvedt¹, Karin Kilian¹, Ragnar Gunnarsson¹, Birgir Gudbrandsson¹, Gudrun Norby¹, Oyvind Molberg² and Øyvind Palm¹, ¹Department of Rheumatology, Oslo University Hospital, Oslo, Norway, OSLO, Norway, ²Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway
Background/Purpose: Survival is decreased in patients with connective tissue diseases (CTDs) and vasculitis, however few studies have compared the mortality between the specific diseases prospectively…
Abstract Number: 1083 • 2015 ACR/ARHP Annual Meeting
Nationwide Trends in Hospitalization and in-Hospital Mortality Associated with Granulomatosis with Polyangiitis (GPA)
Zachary Wallace¹, John H. Stone², Hyon K. Choi³, Na Lu³, Sebastian Unizony³ and Eli Miloslavsky⁴, ¹Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ³Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Division of Rheumatology, Massachusetts General Hopsital, Boston, MA
Background/Purpose: Granulomatosis with polyangiitis (GPA) is associated with severe end-organ damage (e.g., renal failure) and treatment-related complications (e.g., severe infection) which often lead to hospitalization…
Abstract Number: 1084 • 2015 ACR/ARHP Annual Meeting
Improved Survival in Granulomatosis with Polyangiitis: A General Population-Based Study
Zachary Wallace¹, Sebastian Unizony², Na Lu², Hyon K. Choi² and John H. Stone³, ¹Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ²Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: Granulomatosis with polyangiitis (GPA) is associated with an increased risk of mortality. Advances in diagnosis and treatment strategies are thought to improve outcomes in…
Abstract Number: 755 • 2013 ACR/ARHP Annual Meeting
Survival Of Patients With ANCA-Associated Vasculitides In Chronic Dialysis In France From 2002 To 2011: Data From The National Rein Registry
Manon Romeu¹, Cécile Couchoud Sr.², Jean-Christophe Delarozière³, Laurent Chiche Sr.⁴, Jean-Robert Harle⁵, Bertrand Gondoin⁶, Stéphane Burtey⁶, Philippe Brunet⁶, Yvon Berland⁶ and Noémie Jourde-Chiche Sr.⁷, ¹Nephrology, Aix-Marseille Universite, APHM, Marseille, France, ²registre REIN, agence de la biomédecine, paris, France, ³public health, APHM, Marseille, France, ⁴Internal Medicine, CHU Marseille, Marseille, France, ⁵Internal Medicine, APHM, Marseille, France, ⁶Nephrology, APHM, Marseille, France, ⁷Nephrology, Aix-Marseille Université - APHM, Marseille, France
Background/Purpose: Despite dramatic outcome improvement in ANCA-associated vasculitides (AAV), renal involvement is still leading to end-stage renal disease (ESRD) in 20-30% of patients. This study…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].